Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within Interleukin-6 family cytokines
Anne Huber, Amr H. Allam, Christine Dijkstra, Stefan Thiem, Jennifer Huynh, Ashleigh R. Poh, Joshua Konecnik, Saumya P. Jacob, Rita A. Busuttil, Yang Liao, David Chisanga, Wei Shi, Mariah Alorro, Stephen Forrow, Daniele V. F. Tauriello, , Moritz F. Eissmann
This study identifies IL6/STAT3 signaling as a therapeutic target for TP53-mutant gastric cancer by showing its role in metastatic progression driven by mutant Trp53.
Cell Reports · Aug 1, 2024Peer-reviewedCancer Biology